
Fast Five Quiz: Management of GPA
What do you know about the management of GPA? Check your knowledge with this quick quiz.
The latest guidelines from the Kidney Disease Improving Global Outcomes (KDIGO) and European Alliance of Associations for Rheumatology (EULAR) both recommend initiating immunosuppressive therapy in patients with suspected PR3 positive ANCA vasculitis, which is indicative of GPA, even if clinicians are still awaiting biopsy results. Further, EULAR specifically acknowledges that collecting biopsies might not be feasible for each patient with ANCA vasculitis and treatment should 'not be delayed while awaiting histological information.'
Learn more about biopsy for GPA.
KDIGO recommends maintaining therapeutic intervention for 18 months to 4 years following successful remission, which is similar to the EULAR guidelines recommending maintenance therapy for 24-48 months in patients with GPA. They also state, 'longer duration of therapy should be considered in relapsing patients or those with an increased risk of relapse, but should be balanced against patient preferences and risks of continuing immunosuppression.'
Learn more about remission maintenance in GPA.
Infection is a significant concern in ANCA vasculitis, especially regarding immunosuppressive therapies including glucocorticoids that are used to manage the clinical manifestations of the disease. Recent research has shown that chronic nasal carriage of S aureus is significantly higher in patients with the GPA subtype; it has also been shown to be associated with increased endonasal activity and risk for relapse.
Although M catarrhalis, H influenzae, and S pneumoniae do not appear to have a specific association with GPA, data have shown that infection is among the most common causes of death in GPA.
Learn more about infection in GPA.
Data indicate that the GPA subtype is an independent risk factor for disease recurrence. Additionally, KDIGO also considers lower serum creatinine, more extensive disease, PR3 histology (which is associated with higher relapse rates than MPO-positive disease commonly seen in MPA) and ear, nose, and throat involvement as 'baseline factors' for disease recurrence. Factors after diagnosis include history of relapse, ANCA positivity at the end of induction, and rise in ANCA. Treatment-related relapse factors include lower cyclophosphamide exposure, immunosuppressive withdrawal, and glucocorticoid withdrawal.
Learn more about prognosis in GPA.
To ensure disease does not recur into the transplanted tissue, KDIGO specifically recommends delaying kidney transplantation until patients have achieved complete clinical remission for at least 6 months. Further, ANCA positivity or negativity should not factor into this decision, with KDIGO stating, 'the persistence of ANCA should not delay transplantation.' Although a serum creatinine of > 4 mg/dL is a significant predictor of relapse, guidelines recommend considering combination of a monoclonal antibody and an alkylating agent for this indication. Similarly, induction and maintenance of dialysis should also be done under various separate conditions.
Learn more about kidney transplantation for GPA.
Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Reduced capacity at health centre in Pelly Crossing, Yukon, until early September
The health centre in Pelly Crossing, Yukon, will be operating at reduced capacity until Sept. 3, while it only has one nurse on staff. In a Facebook post on Thursday, Selkirk First Nation informed its citizens that the health centre would have reduced services from Aug. 14 to Sept. 3, sharing a notice from the Yukon government. Nigel Allan with Yukon Health and Social Services said the nurse will prioritize emergencies during this time. Non-urgent health care needs, like preventative care or other things that can wait, might need to be rescheduled he said. The reduction in services comes on the heels of a week of reduced service earlier this month when the centre was also operating with only one nurse. The health centre was also closed for several weeks in the spring, and for a day-and-a-half last winter, because no nurses were available. Allan said the Yukon, like many other places in Canada is "dealing with a health HR crisis." "As part of our health HR strategy, we're continuing efforts to recruit health-care providers, including nurses." Allan said nurses working in community health centres often need specialized training to respond to urgent situations, which can make it harder to recruit them. The Yukon government's notice says in emergencies, Pelly residents can call 867-821-444, use the phone outside the health centre or dial 911. For non-emergencies, they can call 811.
Yahoo
an hour ago
- Yahoo
Faro, Yukon without primary care paramedic this weekend
There will be no primary care paramedic or nurses in Faro, Yukon, this weekend. In a post on its Facebook page, the Town of Faro said there will be no primary care paramedic in the community from Aug. 15 to Aug 19. The news comes during a temporary closure of the town's health centre because there are no nurses to staff it. The closure began Aug. 6 and is expected to last until Sept. 5. "Community members should call 911 for any emergencies and EMS [emergency medical service] dispatch will coordinate resources as needed," the post said. During the health centre closure, a primary care paramedic was meant to provide emergency coverage. Now, local volunteers might be the first to respond to emergencies over the weekend. "There will be two volunteer emergency medical responders on call, except [from] between August 18 at 8 p.m. [to] August 19 at 2 p.m.," said Nigel Allan with Yukon Health and Social Services. Allan says EMS will continue to respond to 911 calls in Faro and will dispatch the appropriate responders. "So if that's an EMS team from a neighbouring community or deploy fixed-wing [plane] or helicopter transport from Whitehorse, they'll make that determination as they normally would in any situation for a community." 'We're in the wilderness without health care' Douglas Tutty, a retired nurse and a volunteer firefighter who has lived in Faro since 2018, said primary care paramedics are responsible for assessing patients and determining if they require a medevac. Now, without a primary car paramedic, he said those assessments can't be made in the community. He said EMS will have take someone elsewhere to assess whether they need a medevac, and the closest community where that can happen is in Ross River, an hour and 15 minutes away. Tutty is concerned about the town's capacity to respond to a medical emergency this weekend. "We're in the wilderness and without health care." CBC News has reached out to the mayor of Faro for comment. As of publishing time, he had not done an interview.
Yahoo
an hour ago
- Yahoo
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced that it is monitoring a safety issue with Boston Scientific Corporation's ENDOTAK RELIANCE defibrillation leads, which are used with implantable cardioverter-defibrillators to prevent sudden cardiac death. Earlier this year, the company sent a letter to healthcare providers on July 24, warning that calcification of the leads' expanded polytetrafluoroethylene/ePTFE coating could lead to a gradual increase in low-voltage shock impedance/LVSI. This can reduce the effectiveness of life-saving shocks and even result in patient death. A surgeon examining a patient's brain in an operating room, paramedics nearby. The affected leads were manufactured and distributed between 2002 and 2021 and are no longer available. As of July 24, Boston Scientific had reported 386 serious injuries and 16 deaths linked to this issue. The FDA has categorized this as a potentially high-risk problem and is actively reviewing data to determine further regulatory action. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has 2 segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data